Optimizing Subtyping-Based Therapy in Triple-Negative Breast Cancer
1. The median progression-free survival was improved with the pooled subtyping-based therapy group compared to the control group (11.3 months ...
Tag: advanced breast cancer
Survival in hormone receptor-positive, HER2-negative advanced breast cancer is improved with the addition of capivasertib to fulvestrant therapy
1 .Progression-free survival is improved in patients receiving fulvestrant-capivasertib therapy as compared to fulvestrant-placebo treatment. 2. Overall survival at 18 ...
Trastuzumab deruxtecan superior to physician’s choice treatment in patients with metastatic HER2-positive breast cancer
1. Progression-free survival was greater in the trastuzumab group compared to standard care (17.8 months vs. 6.9 months). 2. Drug-related ...
#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
Click to read this study in The Lancet Oncology.
Fulvestrant for treatment of estrogen receptor-positive, HER2-negative advanced breast cancer may improve progression free survival using ESR1 mutation as guidance
1. Median progression free survival was longer in the fulvestrant and palbociclib group compared to the aromatase inhibitor plus palbociclib ...
#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
Click to read this study in The Lancet Oncology.
#VisualAbstract: Addition of denosumab to neoadjuvant paclitaxel does not improve complete response rate in breast cancer
Click to read this study in JAMA Oncology.
#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
Click to read this study in The Lancet Oncology.
Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer
1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared to trastuzumab emtansine 2. Adverse events were more ...
Ribociclib in addition to letrozole increases overall survival compared to letrozole alone
1. Overall survival was longer in the group receiving ribociclib with letrozole as compared with the placebo group 2. Severe ...